Research programme: controlled release idiopathic pulmonary fibrosis therapeutic - IntelGenxAlternative Names: INT0024; INT0024/2010
Latest Information Update: 16 Jul 2016
At a glance
- Originator IntelGenx Corp.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Canada (PO, Controlled release)